As part of the agreement, Sanofi will provide Alloy with upfront license fees and near-term preclinical milestone payments up to $27.5m.

Sanofi has tapped Alloy Therapeutics to enable development of a central nervous system drug, agreeing to pay $27.5 million in upfront and near-term fees to access an antisense platform.

Alloy Therapeutics Announces a Target Specific Collaboration and License Agreement for use of AntiClastic TM Antisense ...

Sanofi (SNYNF – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Graham Parry from Bank of America Securities reiterated a Buy rating on the ...

A Sanofi cancer drug candidate that was the heart of a $2.5 billion acquisition is heading back to Phase 1/2 testing after an early look at mid-stage clinical data showed what the French ...

UCB and Sanofi have unveiled a scientific and strategic collaboration to discover and develop novel treatments for immune-mediated diseases in areas such as gastroenterology and arthritis.

Sanofi has leapt in to buy Ablynx for €3.9 billion ($4.85bn) outbidding an offer from Novo Nordisk which the European biotech had declined two weeks ago. For Sanofi, the acquisition comes hot on ...

In return, Sanofi will provide Alloy with upfront license fees and near-term preclinical milestone payments up to $27.5 million. Alloy will also be eligible to receive discovery, development ...

In return, Sanofi will provide Alloy with upfront license fees and near-term preclinical milestone payments up to $27.5 million. Alloy will also be eligible to receive discovery, development, and ...

Morningstar brands and products Company Portfolio ...